Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuzuloparib or Capecitabine + Camrelizumab in Adjuvant TNBC
NCT06533384Phase 3Recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluzoparib and capecitabine in triple-negative breast cancer (TNBC) (2 arms), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Invasive Disease-Free Survival at 5 years. Started Aug 2024; status: recruiting.
02
Drugs
fluzoparibcapecitabine
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06533384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06533384.